Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Larimar Therapeutics, Inc. (LRMR)
Company Research
Source: GlobeNewswire
BALA CYNWYD, Pa., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 19,736,842 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 2,574,370 additional shares, at the public offering price of $8.74 per share, the closing price of its common stock on February 13, 2024. The aggregate gross proceeds to Larimar from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $172.5 million. Leerink Partners, Citigroup and Guggenheim Securities acted as joint bookrunning managers for the offering. LifeSci Capital acted as lead manager for the offering. Larimar intends to use the net proceeds from the proposed offering to support the development of nom
Show less
Read more
Impact Snapshot
Event Time:
LRMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LRMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LRMR alerts
High impacting Larimar Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LRMR
News
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.MarketBeat
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $25.00 price target on the stock.MarketBeat
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.MarketBeat
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development [Yahoo! Finance]Yahoo! Finance
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp DevelopmentGlobeNewswire
LRMR
Earnings
- 3/14/24 - Miss
LRMR
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEF
- 4/12/24 - Form PRE
- LRMR's page on the SEC website